Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05549297 · ClinicalTrials.gov registry record · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
A Phase 3 study of Advanced Melanoma, sponsored by Immunocore.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT05549297 is a Phase 3 study of Advanced Melanoma that is actively recruiting participants, run by Immunocore. The registered enrollment target is 540 participants, above the 146-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (270% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05549297, a Phase 3 study of Advanced Melanoma, is actively recruiting participants, sponsored by Immunocore.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.
Conditions Studied
Interventions
- DRUG Tebentafusp
- DRUG Tebentafusp with Pembrolizumab
- DRUG Investigators Choice
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
- Dana Farber Cancer Institute - Boston
Florida
- Mayo Clinic Florida - Jacksonville
- Orlando Health Cancer Institute - Orlando
Kentucky
- St Elizabeth Healthcare (St Elizabeth Medical Center) - Edgewood
- St Elizabeth Healthcare (St Elizabeth Medical - Edgewood
Minnesota
- University of Minnesota Medical Center - Minneapolis
- Mayo Clinic Minnesota - Rochester
New York
- Northwell Health Cancer Institute - Zuckerberg Cancer Center - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University Medical Oncology Clinic - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Arizona
- Mayo Clinic Arizona - Phoenix
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05549297
The ClinicalTrials.gov registry entry for NCT05549297 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (270% higher). The listed sponsor is Immunocore, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Tebentafusp is the first listed.
NCT05549297 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05549297 about?
NCT05549297 is a clinical study titled "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)". The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best sup...
What is the current status of trial NCT05549297?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2022-12-19. Estimated completion is 2028-07.
What conditions does trial NCT05549297 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT05549297?
The interventions under investigation include: Tebentafusp (DRUG), Tebentafusp with Pembrolizumab (DRUG), Investigators Choice (DRUG).
Who is sponsoring clinical trial NCT05549297?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05549297 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
RECRUITING · Phase 3
-
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
RECRUITING · Phase 3
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
RECRUITING · Early Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.